Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men 18 years or older with histologically proven adenocarcinoma of the prostate~* Prior or current androgen deprivation for at least 6 months prior to study entry with either bilateral orchiectomy or being maintained on a stable dose of LHRH (luteinizing hormone-releasing hormone) agonist or antagonist~  * Hot flash frequency of an average of 2 or more per day (average of 14 hot flash episodes per week)~Exclusion Criteria:~* cannot currently be taking serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or monoamine oxidase inhibitors (MAOIs)~  * cannot have uncontrolled hypertension~ * cannot have history of past or current of epilepsy, epilepsy syndrome or other seizure disorder~ * cannot have psychiatric history of mania, hypomania, bipolar disorder or anorexia nervosa~ * cannot be receiving concurrent treatment with amy medications or herbal products being used with the express purpose of treating hot flashes.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Gabapentin (Type: EXPERIMENTAL): Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
- Arm B: Venlafaxine (Type: EXPERIMENTAL): Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).